David J. Harrison, PhD

home / authors / david-j-harrison-phd

Articles

July 11th 2018

Disease-Modifying Antirheumatic Drug Initiation Among Patients Newly Diagnosed With Rheumatoid Arthritis

Machaon Bonafede, PhD, MPH Barbara H. Johnson, MBA Neel Shah, PhD, BPharm David J. Harrison, PhD Derek Tang, PhD, BSPharm Bradley S. Stolshek, PharmD

Only slightly more than half of patients with newly diagnosed rheumatoid arthritis initiated therapy within 1 year.

May 15th 2008

The Cost of Treating Skeletal-Related Events in Patients With Prostate Cancer

Maureen J. Lage, PhD Beth L. Barber, PhD David J. Harrison, PhD Sun Jun, MD, PhD

The analysis examines the annual economic effect of medically treating patients with prostate cancer and subsequent bone metastases.

September 15th 2005

Impact of Atypical Antipsychotics on Outcomes of Care in Schizophrenia

Amie T. Joyce, MPH David J. Harrison, PhD Antony D. Loebel, MD Daniel A. Ollendorf, MPH

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: November 1st 2024 | Updated: November 21st 2024

Table Multiple Myeloma Trials November 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions